Your browser doesn't support javascript.
loading
Clinical observation and literature review of PD-1 antibody in the treatment of 18 patients with advanced tumor / 药学实践杂志
Article 在 Zh | WPRIM | ID: wpr-790727
Responsible library: WPRO
ABSTRACT
Objective To observe the immune effect of PD-1 (programmed death-1) antibody in the treatment of patients with advanced cancer .Methods From October 2015 to March 2016 ,18 patients with advanced tumor were selected to receive the PD-1 antibody treatment in Eastern Hepatobiliary Surgical Hospital .Clinical efficacy ,adverse reactions and progression free survival time were monitored .The quality of life were compared before and after the treatment .Results Among 18 cases , PR 5 cases ,SD 7 cases and PD 6 cases .The KPS scores for quality of life was significantly increased (P<0 .05) after treat-ment .At the end of follow-up ,5 patients died ,2 patients were lost in follow-up ,11 patients survived .The median progression free survival was 2 .6 months (95% CI:1 .8-3 .3 months) .No serious adverse reactions and abnormal laboratory results were reported .Conclusion PD-1 antibody is a safe and effective treatment for advanced tumors .It is well tolerated and has less ad-verse reactions .The randomized control studies with larger samples are needed to further confirm our conclusions .
Key words
全文: 1 索引: WPRIM 研究类型: Clinical_trials 语言: Zh 期刊: Journal of Pharmaceutical Practice 年: 2017 类型: Article
全文: 1 索引: WPRIM 研究类型: Clinical_trials 语言: Zh 期刊: Journal of Pharmaceutical Practice 年: 2017 类型: Article